12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Gardasil: Additional Phase III data

Additional data from a double-blind, placebo-controlled, international Phase III trial in healthy men ages 16-26 showed that Gardasil reduced the incidence of external genital lesions related to HPV types 6, 11, 16 or 18, the primary endpoint, by 65.5% and 90.4% in the intent-to-treat (ITT; n=4,055) and per protocol (PP; n=2,805) populations, respectively. Specifically, there were 27 cases of external genital lesions related to HPV types 6, 11, 16 or 18...

Read the full 332 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >